Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus

Sponsor
Tang-Du Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT02518789
Collaborator
(none)
132
3
12

Study Details

Study Description

Brief Summary

By observing the difference of plasma homovanillic acid concentrations and brain electrical consciousness monitoring Narcotrend index, study the possible mechanism of influencing Etomidate induced myoclonus with Dexmedetomidine pretreatment during general anesthesia induction period.

Condition or Disease Intervention/Treatment Phase
Phase 4

Study Design

Study Type:
Interventional
Anticipated Enrollment :
132 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus During General Anesthesia Induction Period
Study Start Date :
Sep 1, 2015
Anticipated Primary Completion Date :
Aug 1, 2016
Anticipated Study Completion Date :
Sep 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Low-dose Dexmedetomidine

-Pretreatment before anesthesia induction:Intravenous injection dexmedetomidine 0.5 µg/kg,completed within 15 minutes.

Drug: Low-dose Dexmedetomidine
Pretreatment:Intravenous injection dexmedetomidine 0.5 µg/kg ,completed within 15 minutes.
Other Names:
  • Yisi
  • Drug: Etomidate
    After 90 seconds of Pretreatment,intravenous infusion of etomidate fat emulsion 0.3mg/kg. -Does not offer any other drugs within 5 min after completion of etomidate.
    Other Names:
  • Fuerli
  • Drug: midazolam,fentanyl,rocuronium
    Anesthesia induction:Intravenous injection midazolam 0.03 ~ 0.05 mg/kg, fentanyl 5 ~ 8 g/kg, rocuronium 0.6 mg/kg
    Other Names:
  • Liyuexi,Fentanyl Citrate Injection,Aikesong
  • Drug: propofol,remifentanil,cis atracurium
    Anesthesia maintenance:Intravenous infusion of propofol 4 ~ 6 mg/kg/h, remifentanil 0.1 ~ 0.3 μg/kg/min, intermittent intravenous injection of cis atracurium 0.05 ~ 0.1mg/kg
    Other Names:
  • Propofol Injection,Ruifen,Cisatracurium Besylate Injection
  • Experimental: High-dose Dexmedetomidine

    -Pretreatment before anesthesia induction:Intravenous injection dexmedetomidine 1 µg/kg,completed within 15 minutes.

    Drug: High-dose dexmedetomidine
    Pretreatment:Intravenous injection dexmedetomidine 1 µg/kg ,completed within 15 minutes.
    Other Names:
  • Yisi
  • Drug: Etomidate
    After 90 seconds of Pretreatment,intravenous infusion of etomidate fat emulsion 0.3mg/kg. -Does not offer any other drugs within 5 min after completion of etomidate.
    Other Names:
  • Fuerli
  • Drug: midazolam,fentanyl,rocuronium
    Anesthesia induction:Intravenous injection midazolam 0.03 ~ 0.05 mg/kg, fentanyl 5 ~ 8 g/kg, rocuronium 0.6 mg/kg
    Other Names:
  • Liyuexi,Fentanyl Citrate Injection,Aikesong
  • Drug: propofol,remifentanil,cis atracurium
    Anesthesia maintenance:Intravenous infusion of propofol 4 ~ 6 mg/kg/h, remifentanil 0.1 ~ 0.3 μg/kg/min, intermittent intravenous injection of cis atracurium 0.05 ~ 0.1mg/kg
    Other Names:
  • Propofol Injection,Ruifen,Cisatracurium Besylate Injection
  • Placebo Comparator: normal saline Control group

    -Pretreatment before anesthesia induction:Intravenous injection normal saline equal quantity,completed within 15 minutes.

    Drug: normal saline
    Pretreatment:Intravenous injection normal saline equal quantity,completed within 15 minutes.
    Other Names:
  • Sodium Chloride Physiological Solution
  • Drug: Etomidate
    After 90 seconds of Pretreatment,intravenous infusion of etomidate fat emulsion 0.3mg/kg. -Does not offer any other drugs within 5 min after completion of etomidate.
    Other Names:
  • Fuerli
  • Drug: midazolam,fentanyl,rocuronium
    Anesthesia induction:Intravenous injection midazolam 0.03 ~ 0.05 mg/kg, fentanyl 5 ~ 8 g/kg, rocuronium 0.6 mg/kg
    Other Names:
  • Liyuexi,Fentanyl Citrate Injection,Aikesong
  • Drug: propofol,remifentanil,cis atracurium
    Anesthesia maintenance:Intravenous infusion of propofol 4 ~ 6 mg/kg/h, remifentanil 0.1 ~ 0.3 μg/kg/min, intermittent intravenous injection of cis atracurium 0.05 ~ 0.1mg/kg
    Other Names:
  • Propofol Injection,Ruifen,Cisatracurium Besylate Injection
  • Outcome Measures

    Primary Outcome Measures

    1. myoclonus level [when myoclonus occurs after emulsion injection is completed,assessed up to 5 minutes]

      Level 0 :no myoclonus happened; Level 1 :mild, tiny movement, one part of the body such as a finger or shoulder movement; Level 2 :moderate ,2 pieces of different muscle or slight movement of the muscle groups, such as face or legs; Level 3 :severely, 2 pieces or more muscle contracture intensity, such as fast outreach of limbs

    2. Plasma homovanillic acid concentration(PHVA) [Measured when myoclonus occurs after emulsion injection is completed,assessed up to 5 minutes; if myoclonus does not appear,measured at 5 minutes after emulsion injection is completed.]

    Secondary Outcome Measures

    1. Ramsay sedation score [1 min after entering the operating room; 1 min after dexmedetomidine injection is completed; 1 min after emulsion injection is completed;5 minutes after emulsion injection is completed;]

    2. Narcotrend index [1 min after entering the operating room; 1 min after dexmedetomidine injection is completed; 1 min after emulsion injection is completed;5 minutes after emulsion injection is completed;]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 55 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Sign the informed consent

    • American Society of Anesthesiologists (ASA)classification:class I~II;undergoing elective surgery patients

    • Aged between 18 and 55, 49-67 kg weight

    • Body Mass Index(BMI): 20-30 kg/m2

    • Did not use any analgesic or sedatives drugs within 24 h pre-operation

    Exclusion Criteria:
    • Recently patients undergoing sedative drugs and antidepressant treatment

    • Serious vision, hearing impairment or other reasons can not communicate

    • Serious neurological disease, pregnancy, diseases of the cardiovascular system;

    • BMI is Less than the standard 80% or higher than the standard 120%

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Tang-Du Hospital

    Investigators

    • Principal Investigator: LI yumin, PHD, Air Force Military Medical University, China

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Tang-Du Hospital
    ClinicalTrials.gov Identifier:
    NCT02518789
    Other Study ID Numbers:
    • Tangdu-Eto-myo
    First Posted:
    Aug 10, 2015
    Last Update Posted:
    Aug 10, 2015
    Last Verified:
    Aug 1, 2015

    Study Results

    No Results Posted as of Aug 10, 2015